ATE212375T1 - Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung - Google Patents

Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung

Info

Publication number
ATE212375T1
ATE212375T1 AT99911020T AT99911020T ATE212375T1 AT E212375 T1 ATE212375 T1 AT E212375T1 AT 99911020 T AT99911020 T AT 99911020T AT 99911020 T AT99911020 T AT 99911020T AT E212375 T1 ATE212375 T1 AT E212375T1
Authority
AT
Austria
Prior art keywords
production
neurotrophic factor
cntf
ciliary neurotrophic
modified ciliary
Prior art date
Application number
AT99911020T
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE212375T1 publication Critical patent/ATE212375T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
AT99911020T 1998-02-27 1999-02-26 Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung ATE212375T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/031,693 US6472178B1 (en) 1998-02-27 1998-02-27 Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
PCT/US1999/004430 WO1999043813A1 (en) 1998-02-27 1999-02-26 Modified ciliary neurotrophic factor, method of making and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE212375T1 true ATE212375T1 (de) 2002-02-15

Family

ID=21860892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911020T ATE212375T1 (de) 1998-02-27 1999-02-26 Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung

Country Status (13)

Country Link
US (4) US6472178B1 (de)
EP (1) EP1056856B1 (de)
JP (1) JP4330796B2 (de)
AT (1) ATE212375T1 (de)
AU (1) AU749660B2 (de)
CA (1) CA2320402C (de)
DE (1) DE69900816T2 (de)
DK (1) DK1056856T3 (de)
ES (1) ES2168006T3 (de)
IL (2) IL137858A0 (de)
NZ (1) NZ506267A (de)
PT (1) PT1056856E (de)
WO (1) WO1999043813A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
CN1387568A (zh) * 1999-08-13 2002-12-25 里珍纳龙药品有限公司 修饰的睫状神经营养因子及其制备方法和使用方法
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006017156A2 (en) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Methods for identifying a candidate for treatment of obesity
EP1784390A2 (de) 2004-08-13 2007-05-16 Amgen Inc. Substituierte benzokondensierte heterozyklen
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (de) 2005-05-30 2016-03-30 Msd K.K. Neues piperidinderivat
EP1916239A4 (de) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Pyridolverbindung
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
RU2428423C2 (ru) 2005-11-10 2011-09-10 Баниу Фармасьютикал Ко., Лтд. Азазамещенные спиропроизводные
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (de) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diarylketiminderivat
US8592374B2 (en) * 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8796214B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8796215B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (de) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophische Peptide
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
EP3883930A1 (de) 2018-11-20 2021-09-29 Tes Pharma S.r.l. Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
EP0446931A1 (de) 1990-03-14 1991-09-18 FIDIA S.p.A. Menschlicher Wimpern-neuronotrophischer Faktor, für diesen Faktor codierende DNA-Sequenz und Herstellung des Faktors durch rekombinante Technologie
IL98304A (en) 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor
WO1993010233A1 (en) * 1991-11-11 1993-05-27 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
WO1997012635A1 (en) * 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6391312B1 (en) 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes

Also Published As

Publication number Publication date
DE69900816D1 (de) 2002-03-14
HK1033336A1 (en) 2001-08-24
WO1999043813A1 (en) 1999-09-02
IL137858A (en) 2008-04-13
US6472178B1 (en) 2002-10-29
DK1056856T3 (da) 2002-05-06
CA2320402A1 (en) 1999-09-02
US20020123462A1 (en) 2002-09-05
CA2320402C (en) 2010-10-12
PT1056856E (pt) 2002-07-31
US7119066B2 (en) 2006-10-10
NZ506267A (en) 2003-04-29
EP1056856B1 (de) 2002-01-23
JP2002504370A (ja) 2002-02-12
US20030144199A1 (en) 2003-07-31
US6767894B1 (en) 2004-07-27
AU2976399A (en) 1999-09-15
IL137858A0 (en) 2001-10-31
AU749660B2 (en) 2002-07-04
ES2168006T3 (es) 2002-05-16
DE69900816T2 (de) 2002-08-29
JP4330796B2 (ja) 2009-09-16
EP1056856A1 (de) 2000-12-06

Similar Documents

Publication Publication Date Title
DE69900816D1 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
DE69626315D1 (de) Vorrichtung zur herstellung von polsterelementen und deren verwendung
DE58906718D1 (de) Kunststeine, verfahren zur herstellung und verwendung derselben.
ATE185971T1 (de) Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen
DE69019180D1 (de) Organopolysiloxan-Polyharnstoff Blockcopolymer und Methode zu seiner Herstellung.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE69814394D1 (de) Verwendung von levobupivacain
DE59103061D1 (de) Verfahren zur herstellung polyolhaltiger dispersionen und deren verwendung.
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE59002322D1 (de) Verfahren zur herstellung von 1,1,1,3,3,3-hexafluorpropan und 2-chlor-1,1,1,3,3,3-hexafluorpropan.
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
TR200200278T2 (tr) Kalsilitik bileşimler
DE69706157D1 (de) Diarylmethylidenefuran-derivate, verfahren zu deren herstellung und ihre verwendungen in therapie
DE69315868D1 (de) Copolymerlatex, Verfahren zu dessen Herstellung sowie dessen Verwendung
DE3886936D1 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE3873223D1 (de) Benzoxazinyl-triazol-oxide, verfahren zu deren herstellung und deren anwendung.
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
DE69013425D1 (de) Pseudomonasmutant, yzh-Stamm und Verfahren zur Herstellung der 851yzh-Nährlösung mittels dieses Stammes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification